Literature DB >> 8419649

CD4 molecules with a diversity of mutations encompassing the CDR3 region efficiently support human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion.

C C Broder1, E A Berger.   

Abstract

The third complementarity-determining region (CDR3) within domain 1 of the human CD4 molecule has been suggested to play a critical role in membrane fusion mediated by the interaction of CD4 with the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein. To analyze in detail the role of CDR3 and adjacent regions in the fusion process, we used cassette mutagenesis to construct a panel of 30 site-directed mutations between residues 79 and 96 of the full-length CD4 molecule. The mutant proteins were transiently expressed by using recombinant vaccinia virus vectors and were analyzed for cell surface expression, recombinant gp120-binding activity, and overall structural integrity as assessed by reactivity with a battery of anti-CD4 monoclonal antibodies. Cells expressing the CD4 mutants were assayed for their ability to form syncytia when mixed with cells expressing the HIV-1 envelope glycoprotein. Surprisingly in view of published data from others, most of the mutations had little effect on syncytium-forming activity. Normal fusion was observed in 21 mutants, including substitution of human residues 85 to 95 with the corresponding sequences from either chimpanzee, rhesus, or mouse CD4; a panel of Ser-Arg double insertions after each residue from 86 to 91; and a number of other charge, hydrophobic, and proline substitutions and insertions within this region. The nine mutants that showed impaired fusion all displayed defective gp120 binding and disruption of overall structural integrity. In further contrast with results of other workers, we observed that transformant human cell lines expressing native chimpanzee or rhesus CD4 efficiently formed syncytia when mixed with cells expressing the HIV-1 envelope glycoprotein. These data refute the conclusion that certain mutations in the CDR3 region of CD4 abolish cell fusion activity, and they suggest that a wide variety of sequences can be functionally tolerated in this region, including those from highly divergent mammalian species. Syncytium formation mediated by several of the CDR3 mutants was partially or completely resistant to inhibition by the CDR3-directed monoclonal antibody L71, suggesting that the corresponding epitope is not directly involved in the fusion process.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8419649      PMCID: PMC237445     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Morphometric analysis of recombinant soluble CD4-mediated release of the envelope glycoprotein gp120 from HIV-1.

Authors:  R Kirsh; T K Hart; H Ellens; J Miller; S A Petteway; D M Lambert; J Leary; P J Bugelski
Journal:  AIDS Res Hum Retroviruses       Date:  1990-10       Impact factor: 2.205

2.  Crystal structure of an HIV-binding recombinant fragment of human CD4.

Authors:  S E Ryu; P D Kwong; A Truneh; T G Porter; J Arthos; M Rosenberg; X P Dai; N H Xuong; R Axel; R W Sweet
Journal:  Nature       Date:  1990-11-29       Impact factor: 49.962

Review 3.  Recent advances in the polymerase chain reaction.

Authors:  H A Erlich; D Gelfand; J J Sninsky
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

4.  Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains.

Authors:  J H Wang; Y W Yan; T P Garrett; J H Liu; D W Rodgers; R L Garlick; G E Tarr; Y Husain; E L Reinherz; S C Harrison
Journal:  Nature       Date:  1990-11-29       Impact factor: 49.962

5.  Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120.

Authors:  T K Hart; R Kirsh; H Ellens; R W Sweet; D M Lambert; S R Petteway; J Leary; P J Bugelski
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

6.  Evidence by peptide mapping that the region CD4(81-92) is involved in gp120/CD4 interaction leading to HIV infection and HIV-induced syncytium formation.

Authors:  V S Kalyanaraman; D M Rausch; J Osborne; M Padgett; K M Hwang; J D Lifson; L E Eiden
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

7.  A region in domain 1 of CD4 distinct from the primary gp120 binding site is involved in HIV infection and virus-mediated fusion.

Authors:  A Truneh; D Buck; D R Cassatt; R Juszczak; S Kassis; S E Ryu; D Healey; R Sweet; Q Sattentau
Journal:  J Biol Chem       Date:  1991-03-25       Impact factor: 5.157

8.  Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions.

Authors:  L N Callahan; M Phelan; M Mallinson; M A Norcross
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

9.  Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.

Authors:  J P Moore; J A McKeating; W A Norton; Q J Sattentau
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

10.  Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1991-08-01       Impact factor: 14.307

View more
  23 in total

1.  Research on anti-HIV-1 agents. Investigation on the CD4-Suradista binding mode through docking experiments.

Authors:  F Manetti; F Corelli; N Mongelli; A L Borgia; M Botta
Journal:  J Comput Aided Mol Des       Date:  2000-05       Impact factor: 3.686

2.  Recombinant vaccinia viruses. Design, generation, and isolation.

Authors:  C C Broder; P L Earl
Journal:  Mol Biotechnol       Date:  1999-12-15       Impact factor: 2.695

3.  Postbinding events mediated by human immunodeficiency virus type 1 are sensitive to modifications in the D4-transmembrane linker region of CD4.

Authors:  S Moir; J Perreault; L Poulin
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 4.  Virus receptors: implications for pathogenesis and the design of antiviral agents.

Authors:  L C Norkin
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

5.  Functional epitope analysis of the human CD4 molecule: antibodies that inhibit human immunodeficiency virus type 1 gene expression bind to the immunoglobulin CDR3-like region of CD4.

Authors:  M Benkirane; M Hirn; D Carrière; C Devaux
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Phorbol ester-induced down modulation of tailless CD4 receptors requires prior binding of gp120 and suggests a role for accessory molecules.

Authors:  H Golding; D S Dimitrov; J Manischewitz; C C Broder; J Robinson; S Fabian; D R Littman; C K Lapham
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

Review 7.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

Review 8.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

9.  Calcium ions are required for cell fusion mediated by the CD4-human immunodeficiency virus type 1 envelope glycoprotein interaction.

Authors:  D S Dimitrov; C C Broder; E A Berger; R Blumenthal
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

10.  Viral sequestration of antigen subverts cross presentation to CD8(+) T cells.

Authors:  Eric F Tewalt; Jean M Grant; Erica L Granger; Douglas C Palmer; Neal D Heuss; Dale S Gregerson; Nicholas P Restifo; Christopher C Norbury
Journal:  PLoS Pathog       Date:  2009-05-29       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.